Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Go back to Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval| DYNEGY, Inc. (NASDAQ: DYN) | Delayed: 20.87 +1.07 (5.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.80 | 52 Week High | $22.01 | |||
| Open | $20.17 | 52 Week Low | $7.01 | |||
| Day High | $20.99 | P/E | N/A | |||
| Day Low | $20.11 | EPS | $0.00 | |||
| Volume | 2,560,456 | |||||
